• Locations
  • Conditions
  • Treatments
  • Institutions
  • Resources
  • For researchers
  • About us
Facebook link logoLinkedin link logo
Terms of usePrivacy policy
All Clinical Trials 2026All Rights reservedPrivacy PolicyTerms of Use
LocationsTexasArizonaCaliforniaNew YorkMassachusettsFloridaNew JerseyUtahAll locationsConditionsOncologyAlzheimer'sDiabetesMultiple SclerosisArthritisHepatitis CCOPDDepressionAll conditionsTreatmentsWeight LossStem CellsVaccinesSleep ApneaMedical DevicesIVFDentalDrug AddictionAll treatmentsInstitutionsPfizerModernaNIHUCLAStanfordM.D. AndersonLabcorpAll institutionsResourcesBlogFAQMedical advisors
Terms of usePrivacy policy
All Clinical Trials 2026All Rights reservedPrivacy PolicyTerms of Use
  1. Clinical trials
  2. A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
  3. Apply

Zipalertinib vs. PlaceboA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Basic information
Step 1/5

Provide your basic information